NASDAQ:CASC - Cascadian Therapeutics Stock Price, Forecast & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Cascadian Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $10.02 +10.02 (+∞) (As of 03/19/2018) Add Today's Range$10.02Now: $10.02▼$10.0250-Day Range N/A52-Week Range$3.18Now: $10.02▼$10.21VolumeN/AAverage Volume1.09 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company's clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryBiotechnology SectorN/A Current SymbolNASDAQ:CASC Previous Symbol CUSIP68232410 CIK1412067 Webhttp://www.cascadianrx.com/ Phone+1-206-8012100Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding SharesN/AMarket CapN/A Next Earnings DateN/A OptionableNot Optionable Receive CASC News and Ratings via Email Sign-up to receive the latest news and ratings for CASC and its competitors with MarketBeat's FREE daily newsletter. Cascadian Therapeutics (NASDAQ:CASC) Frequently Asked Questions What is Cascadian Therapeutics' stock symbol? Cascadian Therapeutics trades on the NASDAQ under the ticker symbol "CASC." How were Cascadian Therapeutics' earnings last quarter? Cascadian Therapeutics Inc (NASDAQ:CASC) issued its quarterly earnings results on Wednesday, November, 8th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.01. During the same quarter last year, the business earned ($0.09) earnings per share. View Cascadian Therapeutics' Earnings History. Has Cascadian Therapeutics been receiving favorable news coverage? News coverage about CASC stock has trended extremely negative recently, according to InfoTrie Sentiment. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Cascadian Therapeutics earned a daily sentiment score of -4.5 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the next several days. View News Stories for Cascadian Therapeutics. Who are some of Cascadian Therapeutics' key competitors? Some companies that are related to Cascadian Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). What other stocks do shareholders of Cascadian Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cascadian Therapeutics investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Athabasca Oil (ATH), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), NIC (EGOV), ALJ Regional (ALJJ), Transocean (RIG) and Gran Tierra Energy (GTE). Who are Cascadian Therapeutics' key executives? Cascadian Therapeutics' management team includes the folowing people: Christopher S. Henney Ph.D., Chairman of the Board (Age 76)Scott D. Myers, President, Chief Executive Officer, Director (Age 51)Julia Marie Eastland, Chief Financial Officer, Vice President - Corporate Development, Secretary (Age 51)Gary W. Christianson, Chief Operating Officer (Age 61)Scott Peterson Ph.D., Chief Scientific Officer (Age 54)Robert W. Azelby, Director (Age 49)Gwendolyn A. Fyfe M.D., Independent Director (Age 65)Steven P. James, Independent Director (Age 58)Ted W. Love M.D., Independent Director (Age 58)Daniel Keith Spiegelman, Independent Director (Age 58) What is Cascadian Therapeutics' stock price today? One share of CASC stock can currently be purchased for approximately $10.02. What is Cascadian Therapeutics' official website? The official website for Cascadian Therapeutics is http://www.cascadianrx.com/. How can I contact Cascadian Therapeutics? Cascadian Therapeutics' mailing address is 3101 Western Ave Ste 600, SEATTLE, WA 98121-3047, United States. The biopharmaceutical company can be reached via phone at +1-206-8012100 or via email at [email protected] MarketBeat Community Rating for Cascadian Therapeutics (NASDAQ CASC)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 287 (Vote Outperform)Underperform Votes: 319 (Vote Underperform)Total Votes: 606MarketBeat's community ratings are surveys of what our community members think about Cascadian Therapeutics and other stocks. Vote "Outperform" if you believe CASC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CASC will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/26/2020 by MarketBeat.com StaffFeatured Article: What is a back-end load?